Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- China Spinal Cord Injury Network
- Enrollment
- 12
- Locations
- 2
- Primary Endpoint
- National Institutes of Health Stroke Scale
- Last Updated
- 8 years ago
Overview
Brief Summary
The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear cells (UCBMC) treatment of chronic ischemic stroke.
Detailed Description
This is an open-label, delayed-treatment trial. A total of 12 subjects fulfill the inclusion and exclusion criteria will be recruited and randomly assigned into two treatment group. Group A (early-treatment group) will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0. Group B (delayed-treatment group) will participate in 6 months observation before the UCBMC transplantation at Month 6. All subjects will be followed up for 18 months from enrollment at Day 0. Long-term follow-up will be carried up to 36 months if applicable. The adverse events and safety parameters will be collected and recorded. In addition, the stroke scores , gait and brain MRI will be obtained before and after the treatment to assess the safety and potential treatment effect of UCBMC in chronic ischemic stroke.
Investigators
Eligibility Criteria
Inclusion Criteria
- •either gender, age 35 -65 years old;
- •ischemic stroke \> 6 months and \< 60 months;
- •stable hemiplegia or hemiparesis condition \> 3 months;
- •stroke-induced clinical deficits affecting motor, perceptual, or language functions, with NIHSS of 5-15;
- •stroke in the middle cerebral artery territory;
- •subjects able to understand, sign and date the informed consent form
Exclusion Criteria
- •non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or intraventricular hemorrhage;
- •pregnant or lactating women;
- •alcohol or drug abuse in previous 3 months;
- •significant medical diseases or infections;
- •current participation in another investigational study or taking any investigational drug within last 4 weeks before the screening;
- •unavailability of HLA-matched umbilical cord blood unit;
- •investigator suggests that the subject would not suitable to perform the surgery or participate in the study
Outcomes
Primary Outcomes
National Institutes of Health Stroke Scale
Time Frame: 18 months, up to 36 months
The change from the baseline in National Institutes of Health Stroke Scales
Secondary Outcomes
- Barthel Index(18 months)
- European Stroke Scale (ESS)(18 months, up to 36 months if applicable)
- Min-Mental State Examination (MMSE)(18 months)
- MRI(18 months)